Shanghai - Delayed Quote CNY

Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS)

Compare
179.60
-13.10
(-6.80%)
At close: January 10 at 3:00:04 PM GMT+8
Loading Chart for 688506.SS
DELL
  • Previous Close 192.70
  • Open 194.00
  • Bid 179.36 x --
  • Ask 179.60 x --
  • Day's Range 177.35 - 196.00
  • 52 Week Range 96.21 - 246.31
  • Volume 1,631,834
  • Avg. Volume 1,451,653
  • Market Cap (intraday) 72.02B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 18.99
  • EPS (TTM) 9.46
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally. Sichuan Biokin Pharmaceutical Co.,Ltd. was founded in 2006 and is based in Chengdu, China.

www.baili-pharm.com

2,086

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688506.SS

View More

Performance Overview: 688506.SS

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

688506.SS
6.80%
SSE Composite Index
7.01%

1-Year Return

688506.SS
40.05%
SSE Composite Index
9.51%

3-Year Return

688506.SS
524.70%
SSE Composite Index
11.48%

5-Year Return

688506.SS
524.70%
SSE Composite Index
2.38%

Compare To: 688506.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688506.SS

View More

Valuation Measures

As of 1/10/2025
  • Market Cap

    72.02B

  • Enterprise Value

    68.59B

  • Trailing P/E

    18.97

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.26

  • Price/Book (mrq)

    16.98

  • Enterprise Value/Revenue

    11.73

  • Enterprise Value/EBITDA

    16.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    64.99%

  • Return on Assets (ttm)

    60.19%

  • Return on Equity (ttm)

    163.15%

  • Revenue (ttm)

    5.85B

  • Net Income Avi to Common (ttm)

    3.8B

  • Diluted EPS (ttm)

    9.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.98B

  • Total Debt/Equity (mrq)

    36.55%

  • Levered Free Cash Flow (ttm)

    2.18B

Research Analysis: 688506.SS

View More

People Also Watch